What is Zacks Research’s Estimate for STERIS Q3 Earnings?

STERIS plc (NYSE:STE) – Research analysts at Zacks Research lifted their Q3 2026 earnings estimates for shares of STERIS in a research report issued on Thursday, June 12th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $2.65 per share for the quarter, up from their previous estimate of $2.53. The consensus estimate for STERIS’s current full-year earnings is $9.08 per share. Zacks Research also issued estimates for STERIS’s Q4 2026 earnings at $2.86 EPS, FY2026 earnings at $10.36 EPS, Q4 2027 earnings at $2.78 EPS and FY2028 earnings at $12.38 EPS.

STE has been the topic of a number of other research reports. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday. Jefferies Financial Group started coverage on shares of STERIS in a research note on Thursday, May 29th. They set a “hold” rating and a $263.00 price target on the stock. Needham & Company LLC reissued a “hold” rating on shares of STERIS in a research report on Monday, April 7th. Citigroup reaffirmed an “outperform” rating on shares of STERIS in a report on Friday, May 16th. Finally, JMP Securities lifted their target price on STERIS from $265.00 to $280.00 and gave the company a “market outperform” rating in a research report on Friday, May 16th. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, STERIS has an average rating of “Moderate Buy” and a consensus target price of $263.83.

STERIS Trading Down 0.5%

Shares of NYSE:STE opened at $241.16 on Monday. STERIS has a 52-week low of $200.98 and a 52-week high of $252.79. The stock has a market capitalization of $23.72 billion, a price-to-earnings ratio of 51.20 and a beta of 0.94. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.40 and a current ratio of 2.13. The stock’s 50-day simple moving average is $232.76 and its two-hundred day simple moving average is $222.76.

STERIS (NYSE:STE) last released its quarterly earnings data on Wednesday, May 14th. The medical equipment provider reported $2.74 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.15. STERIS had a net margin of 8.66% and a return on equity of 13.91%. The firm had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.47 billion. During the same period in the previous year, the company earned $2.58 earnings per share. The firm’s quarterly revenue was up 5.7% on a year-over-year basis.

Hedge Funds Weigh In On STERIS

Several hedge funds have recently modified their holdings of STE. Geneos Wealth Management Inc. increased its holdings in STERIS by 416.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 104 shares during the last quarter. Avalon Trust Co purchased a new position in shares of STERIS during the fourth quarter valued at about $30,000. Grove Bank & Trust increased its holdings in shares of STERIS by 4,733.3% in the first quarter. Grove Bank & Trust now owns 145 shares of the medical equipment provider’s stock worth $33,000 after purchasing an additional 142 shares during the last quarter. Human Investing LLC bought a new stake in shares of STERIS in the fourth quarter worth about $31,000. Finally, Zions Bancorporation National Association UT purchased a new stake in shares of STERIS in the first quarter worth about $37,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Buying and Selling

In related news, SVP Cary L. Majors sold 12,828 shares of the business’s stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $250.08, for a total value of $3,208,026.24. Following the transaction, the senior vice president now directly owns 11,372 shares of the company’s stock, valued at approximately $2,843,909.76. The trade was a 53.01% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Daniel A. Carestio sold 17,626 shares of the company’s stock in a transaction that occurred on Thursday, June 5th. The stock was sold at an average price of $242.56, for a total value of $4,275,362.56. Following the completion of the transaction, the chief executive officer now owns 51,385 shares of the company’s stock, valued at $12,463,945.60. The trade was a 25.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.14% of the stock is currently owned by insiders.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 26th. Investors of record on Tuesday, June 10th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a dividend yield of 0.95%. The ex-dividend date is Tuesday, June 10th. STERIS’s dividend payout ratio (DPR) is 36.77%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.